2-OHOA With RT and TMZ for Adults With Glioblastoma
Status:
Recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects
with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and
safety of 2-OHOA versus placebo, given with standard of care (SoC) therapy of radiation
therapy plus temozolomide (TMZ), followed by an adjuvant treatment of 6 month period of TMZ
and then 2-OHOA or placebo in monotherapy.
Covance LIPODOM THERAPEUTICS Northern Institute for Cancer Research, Newcastle SEQUENCING MULTIPLEX Specialized Medical Services (SMS)-Oncology BV Theradis Theradis pharma